Abstract
Human immunodeficiency virus type 1 (HIV-1) requires a chemokine receptor (CCR5 or CXCR4) as a coreceptor not only for initiate viral entry but also protecting highly conserved neutralization epitopes from the attack of neutralizing antibodies. Over the past decade, many studies have provided new insights into the HIV entry mechanism and have focused on developing an effective vaccine strategy. However, to date, no vaccine that can provide protection from HIV-1 infection has been developed. One reason for the disappointing results has been the inability of current vaccine candidates to elicit a broadly reactive immunity to viral proteins such as the envelope (env) protein. Here, we propose that chemokine receptors are attractive targets of vaccine development because their structures are highly conserved and that our synthetic cycloimmunogens can mimic conformational-specific epitopes of undecapeptidyl arches (UPAs: R168-C178 in CCR5, N176-C186 in CXCR4) and be useful for HIV-1 novel vaccine development.
Keywords: Cycloimmunogen, HIV-1, conformational epitope, CCR5, CXCR4
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Immunoreactive Cycloimmunogen Design Based on Conformational Epitopes Derived from Human Immunodeficiency Virus Type 1 Coreceptors:Cyclic Dodecapeptides Mimic Undecapeptidyl Arches of Extracellular Loop-2 in Chemokine Receptor and Inhibit Human Immunodeficiency Virus Type 1 Infection
Volume: 7 Issue: 2
Author(s): Shogo Misumi, Nobutoki Takamune and Shozo Shoji
Affiliation:
Keywords: Cycloimmunogen, HIV-1, conformational epitope, CCR5, CXCR4
Abstract: Human immunodeficiency virus type 1 (HIV-1) requires a chemokine receptor (CCR5 or CXCR4) as a coreceptor not only for initiate viral entry but also protecting highly conserved neutralization epitopes from the attack of neutralizing antibodies. Over the past decade, many studies have provided new insights into the HIV entry mechanism and have focused on developing an effective vaccine strategy. However, to date, no vaccine that can provide protection from HIV-1 infection has been developed. One reason for the disappointing results has been the inability of current vaccine candidates to elicit a broadly reactive immunity to viral proteins such as the envelope (env) protein. Here, we propose that chemokine receptors are attractive targets of vaccine development because their structures are highly conserved and that our synthetic cycloimmunogens can mimic conformational-specific epitopes of undecapeptidyl arches (UPAs: R168-C178 in CCR5, N176-C186 in CXCR4) and be useful for HIV-1 novel vaccine development.
Export Options
About this article
Cite this article as:
Misumi Shogo, Takamune Nobutoki and Shoji Shozo, Immunoreactive Cycloimmunogen Design Based on Conformational Epitopes Derived from Human Immunodeficiency Virus Type 1 Coreceptors:Cyclic Dodecapeptides Mimic Undecapeptidyl Arches of Extracellular Loop-2 in Chemokine Receptor and Inhibit Human Immunodeficiency Virus Type 1 Infection, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187153007780832127
DOI https://dx.doi.org/10.2174/187153007780832127 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Clinical PET Imaging of Insulinoma and Beta-Cell Hyperplasia
Current Pharmaceutical Design The Design of Cationic Lipids for Gene Delivery
Current Pharmaceutical Design Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Inhibition of Human Aromatase by Myosmine
Drug Metabolism Letters A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab
Endocrine, Metabolic & Immune Disorders - Drug Targets Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Engineering Biomimetic Materials for Islet Transplantation
Current Diabetes Reviews Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Selective Thyroid Hormone Receptor Modulators
Current Topics in Medicinal Chemistry Roles of Perilipins in Diseases and Cancers
Current Genomics Application of High Performance Liquid Chromatography for Hydrolytic Stability Assessment of Selected Antibiotics in Aqueous Environment
Current Analytical Chemistry Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research